SK pharmteco203Established in 2019 by SK Inc., SK pharmteco is a U.S.-based operational holding company leading SK Group’s global CDMO platform. The company combines financial strength, global infrastructure, and technical expertise to deliver high-quality development and manufacturing solutions across critical therapeutic modalities.
SK pharmteco is strategically expanding its viral vector capabilities to support the rapid growth of gene therapy and in vivo genetic medicine programs. The company provides robust process development, scalable GMP manufacturing, and regulatory-aligned production platforms designed to transition programs efficiently from early clinical stages to commercial supply.
With a strong foundation in quality systems, operational excellence, and global compliance, SK pharmteco positions itself as a reliable long-term manufacturing partner for innovators navigating the complexity of viral vector production.
In parallel, SK pharmteco maintains established expertise in small molecule and high-potency API manufacturing, enabling integrated support for partners with diverse or multi-modality pipelines.
Backed by SK Group’s long-term investment strategy and global footprint, SK pharmteco offers both the agility of a focused CDMO and the stability of a major international industrial group, a combination that differentiates it in the evolving advanced therapy manufacturing landscape.
